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Effect of the UK government’s 2-week target on waiting times in
women with breast cancer in southeast England
D Robinson*,1, CMJ Bell1, H Møller1 and I Basnett2
1Thames Cancer Registry, Guy’s King’s and St Thomas’ School of Medicine, Capital House, 42 Weston Street, London SE1 3QD, UK; 2Camden & Islington
Health Authority, 110 Hampstead Road, London NW1 2LJ, UK
A government target of a maximum 2-week wait for women referred urgently with suspected breast cancer was introduced in April
1999. We have assessed changes in the distributions of waiting times and the proportions of cases meeting proposed targets before
and after this date, using clinical audit data on 5750 women attending 19 hospitals in southeast England during the period July 1997–
December 2000, who were subsequently found to have breast cancer. The proportion of cases being seen within 2 weeks of referral
rose from 66.0 to 75.2%, and the median wait to first appointment fell from 13.6 to 12.3 days, following the introduction of the
government target. The proportion of cases waiting 5 weeks or less between first hospital appointment and treatment fell from 83.8
to 80.3%, and median waits for treatment increased from 21.4 to 24.1 days. We also examined the effects on waiting times of various
sociodemographic and care related factors. A total of 85.7% of screening cases vs 67.9% of symptomatic cases were seen within 2
weeks, and 95.0% of cases treated with tamoxifen received treatment within 5 weeks, as opposed to 77.6% of cases treated with
surgery, 81.2% of chemotherapy cases and 52.8% of radiotherapy cases. While waiting times from GP referral to first hospital
appointment have improved since the introduction of the government target, times from first appointment to treatment have
increased, and consequently total waiting times have changed little.
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On 1 April 1999, the UK Government introduced a ‘guaranteed’
2-week maximum wait for assessment by a hospital consultant for
women referred urgently by their GP with suspected breast cancer.
Since this date, each hospital has been required to submit data to
the Department of Health, and the performance of hospitals
against the target is being monitored and documented on the
Department’s web site (www.doh.gov.uk/cancerwaits/).
However, breast clinics have been concerned for some time
about increasing numbers of referrals from GPs (Patel et al, 2000).
The predictive value of symptoms is poorly defined in general
practice (Jones et al, 2001), and only 9– 10% of referrals are
subsequently found to have breast cancer (Patel et al, 2000;
Sauven, 2001). Of these confirmed cancers, about a third are not
referred urgently (Sauven, 2001), and there is concern that
pressure to meet the target for urgent referrals may have resulted
in longer waits for such nonurgently referred cases (Thrush et al,
2002). After the government target was introduced in April 1999,
median waits for routine referrals increased from 2 to 3 weeks in
Rotherham (Cant and Yu, 2000), and in Eastbourne they rose from
4 to 8 weeks (Khawaja and Allan, 2000).
To reduce anxiety for women with suspected cancer, all stages of
the care pathway need speeding up. This was acknowledged in the
NHS Cancer Plan (Department of Health, 2000), which set further
targets for breast cancer patients: namely that all patients should
be treated within 1 month of diagnosis by 2001, and within 2
months of urgent GP referral by 2002. These new targets are to be
extended to all cancers by 2005.
Since 1996, the health authorities in and around London have
been working with the Thames Cancer Registry to facilitate a
regional programme of audit of breast cancer management, which
aims to collect standard, comparative data and monitor quality of
care (Bell and Ma, 1997), and to improve care and outcomes
through an evidence-based implementation of guideline practice
(Grol and Grimshaw, 1999). The project database permits the
evaluation of waiting times from GP referral to first out patient
appointment and to treatment in women with breast cancer, and
enables exploration of the waits they experienced before and after
the introduction of the government 2-week waiting time target on
1 April 1999.
MATERIALS AND METHODS
The study area consists of the part of London north of the River
Thames together with the counties of Hertfordshire and North
Essex, and has a resident population of around seven million
people. The 28 acute hospitals in this area have been collecting
data prospectively on all new incident breast cancers since 1996. A
standard clinical data set has been agreed regionally, which is
similar to the current British Association of Surgical Oncology
(BASO) data set. Data are collected by hospital staff and submitted
annually to Thames Cancer Registry to be pooled, collated and
analysed. Comparative information about case-mix and clinical
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quality indicators is fed back to the multidisciplinary breast teams
at the hospitals (Bell et al, 2000). The present analysis is based on a
subset of the data held on the central audit database at the
Registry, which at the end of 2001 consisted of 13 234 records of
female breast cancer cases first seen between January 1996 and
December 2000 in one of the 28 hospitals.
Three waiting times were defined as follows: the referral wait is
the interval between the date that the GP referral letter was
sent and the date of first hospital attendance; the treatment
wait is the interval between the date of first attendance and
the date of first treatment of any kind; and the total wait is the
interval between GP referral date and first treatment date. All
waiting times were calculated as the number of days between
relevant dates.
The NHS Cancer Plan sets targets of 2 weeks for the wait from
referral to first appointment, 4 weeks from diagnosis to treatment
and 2 months from referral to treatment. We have accordingly
applied targets of 2 and 9 weeks for the referral wait and total wait,
respectively. As date of diagnosis was not part of our data set, we
have used date of first attendance as a surrogate, and applied a
target of 5 weeks to the treatment wait.
Comparisons before and after the introduction of the govern-
ment target were made by stratifying cases into those with GP
referrals received between July 1997 and March 1999 and those
received between April 1999 and December 2000, thus giving two
equal 21-month intervals on either side of the introduction date of
1 April 1999.
To reduce bias due to heterogeneity between hospitals, only
those that had consistently provided data over the period being
examined and for which waiting times were available for the
majority (470%) of their cases were included. This helps to avoid
situations where, for example, a poorly performing hospital
provides data in the ‘pretarget’, but not in the ‘post-target’ period,
leading to an exaggerated estimate of improvement following the
introduction of the targets.
In order to maximise coverage, in cases where only one of the
dates (GP referral sent and referral received) was present, the other
was estimated on the basis of the finding that the median
difference between these two dates in cases with both present was 1
day. Some cases were excluded because their waiting times were
greater than 6 months. This was done to avoid bias due to the
timing of data submission to the registry 6 months after the end of
each calendar year, which resulted in a maximum possible waiting
time of 6 months for cases seen at the end of a year. The
proportions of cases excluded as a result of this truncation were
low (0.1% for referral wait, 0.8% for treatment wait and 1.2% for
total wait). The maximum observed waiting times were 281, 328
and 342 days for the referral, treatment and total waits,
respectively. There were no significant differences in the propor-
tions excluded for any of the waiting times between the periods
before and after the introduction of the targets.
The final data set for analysis consisted of 5750 cases from 19
hospitals.
Waiting times were assessed in terms of both mean and median
values (the distributions being highly skewed) and the proportions
of cases meeting the relevant target values. Although untrans-
formed mean values are displayed in the tables, significance tests
were performed on log transformed data.
Changes in the overall distributions of the waiting times were
examined by calculating the Kaplan –Meier survival curves
(Kaplan and Meier, 1958), using attendance at hospital (referral
wait) or commencement of treatment (treatment wait and total
wait) as the outcome event. The survival curves were inverted to
produce a more readily interpretable plot, showing the proportion
of cases seen or treated within a given time. Differences in
distributions were assessed by the log-rank test (Peto et al, 1977).
All analyses were performed using the Stata statistical package
(Statacorp, 2001).
A number of factors thought likely to affect the waiting times
were studied: the patient’s age at referral, deprivation index,
priority (urgency of referral as assigned by the referring GP),
screen detected or otherwise, the size of the clinic attended
(throughput) and type of first treatment. Throughput was based on
the average annual caseload over the 4 year period 1997–2000 of
the hospital attended by the patient, and deprivation was assessed
by assigning a quintile of the Carstairs Index (Carstairs and
Morris, 1989) to each woman on the basis of her postcode of
residence. Analyses were carried out by testing for differences
between the proportions seen within the relevant targets at
different levels of the factor concerned, using data from the
complete period (July 1997–December 2000). Priority was not
initially among the data items collected, and thus was only
available on a small subset of 543 (9.4%) patients seen in the year
2000.
RESULTS
Table 1 shows the changes in the three waiting times following the
1 April 1999 deadline, in terms of the mean and median waiting
times and the proportion meeting the relevant target. For all three
measures the referral wait showed a highly significant improve-
ment, with decreasing waiting times and an increasing proportion
meeting the 2-week target. The treatment wait showed a significant
deterioration on all three measures. The changes in the total wait
were small, but in the direction suggesting a worsening of total
waiting times.
Figures 1 and 2 show the inverse Kaplan–Meier plots for the
referral wait and treatment wait, respectively, for the periods
before and after 1 April 1999. There was a significant (Po0.001)
distributional shift towards shorter waiting times for the referral
wait and longer times for the treatment wait following the
introduction of the target. Examination of the tails of the
distributions showed that there was no suggestion of an increase
in the number of cases waiting for very long periods. No significant
change in the distribution of total wait values was seen (not
shown).
Considerable variation was seen between hospitals. In eight of
the 19 hospitals, the proportion meeting the target for the referral
wait increased by more than 10 percent following the April 1999
deadline, but the proportion meeting the corresponding target for
the treatment wait deteriorated significantly in half of these. Only
two hospitals showed a substantial improvement (45% increase in
the proportion meeting the target) in both waiting times, and one
hospital displayed a substantial deterioration in both.
Table 2 shows the proportions meeting the relevant targets in
relation to the various explanatory factors studied. By age, the
highest proportions meeting the target were seen in the 50– 64
years age group for the referral wait, and the 65þ years age group
for the treatment wait. Although for the referral wait a higher
proportion of Carstairs group 1 cases (the most affluent) were seen
within 2 weeks when compared to the other groups, the overall test
for differences between the Carstairs quintile groups was
nonsignificant (P¼ 0.7). For both referral wait and treatment wait,
a significantly higher proportion of women attending high
throughput hospitals met the targets. A significantly greater
proportion of urgent referrals were seen on target for the referral
wait.
There were large differences for the referral wait in relation to
mode of presentation, with a larger proportion of women with
screen-detected cancers meeting the target. Likewise, for the
treatment wait large differences were seen for different types of
treatment. Approximately 95% of those receiving tamoxifen
or endocrine treatment were treated within 5 weeks, as
opposed to only 53% of those receiving radiotherapy as their first
treatment.
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The inverse Kaplan –Meier plots for referral wait in relation to
mode of presentation and treatment wait in relation to treatment
type are shown in Figures 3 and 4, respectively. The distributional
differences are striking, and log-rank tests were highly significant.
DISCUSSION
There has been a significant improvement in waiting times from
GP referral to first hospital appointment in women with breast
Table 1 Waiting time statistics for women with breast cancer, before and after 1 April 1999
Period Before (July 1997–March 1999) After (April 1999–December 2000) Test for difference
Referral wait
Proportion meeting target (%) 66.0 75.2 ***
Mean (days) 13.6 12.3 ***
Median (days 11 10 ***
Interquartile range (days) 6–18 6–14
Treatment wait
Proportion meeting target (%) 83.8 80.3 **
Mean (days) 21.4 24.1 ***
Median (days) 16 20 ***
Interquartile range (days) 7–27 9–31
Total wait
Proportion meeting target (%) 89.1 88.5 (NS)
Mean (days) 35.0 36.4 *
Median (days) 29 30 **
Interquartile range (days) 17–44 18–45
No. of cases 2712 3038
***Po0.001; **0.001oPo0.01; *0.01oPo0.025; (NS)¼ P40.5.
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Figure 1 Distributions for referral wait, before and after 1 April 1999.
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Figure 2 Distributions for treatment wait, before and after 1 April 1999.
Table 2 Proportions (%) meeting relevant targetsa by various factors
(July 1997–December 2000)
Factor Referral wait Treatment wait
Age (years) (n¼ 5592)
o50 64.2 77.3
50–64 76.5 80.5
65+ 70.0*** 85.6***
Carstairs quintile (n¼ 3458)
1 70.7 79.8
2 65.7 80.4
3 66.8 82.8
4 67.1 82.7
5 67.5(NS) 82.7(NS)
Trust throughput (n¼ 5750)
150 69.7 80.6
4150 72.1* 83.3**
Priority (n¼ 543)
Urgent 77.2
Nonurgent 41.2***
Mode of presentation (n¼ 5450)
Screening 85.7
Symptomatic 67.9
Incidental 77.7***
Type of treatment (n¼ 5701)
Surgery 77.6
Chemotherapy 81.2
Radiotherapy 52.8
Tamoxifen 95.0***
Test for heterogeneity: ***Po0.001; **0.001oPo0.01; *0.01oPo0.025;
(NS)¼ P40.5. aTwo week target for referral wait; 5 week target for treatment wait.
Waiting times for breast cancer
D Robinson et al
494
British Journal of Cancer (2003) 89(3), 492 – 496 & 2003 Cancer Research UK
C
lin
ic
a
l
cancer following the introduction of the ‘guaranteed’ 2-week
maximum wait in April of 1999. However, there has been a
corresponding deterioration in the waiting times between first
hospital appointment and treatment, with the result that total
waiting times remain relatively unchanged.
There was no evidence that any group (e.g. nonurgent cases) was
particularly disadvantaged by the introduction of the 2-week wait
target. When the distributions of referral waiting times before and
after the 1 April 1999 deadline were compared, there was no
suggestion of the crossover that would be expected if a substantial
number of cases were being made to wait longer. There was a shift
towards shorter waits in the later period across the whole range of
waiting times.
If the aim of urgent referral is to detect cancers quickly, as well
as assuage anxiety, then it may be that priority should be assigned
by consultants. We have found evidence to suggest that
consultants are better than GPs at correctly prioritising the
patients with cancer, as suggested previously by Sauven (2001). In
our data set, 340 cases had data on priority assigned by both
consultant and GP in the post-target period. For the vast majority
of these (314, 92%), the GP and consultant concurred about
urgency. However, 21 women (6%) referred as nonurgent by the
GP were designated as urgent by the consultant. This small group
of women had a mean wait of 20.9 days (compared with 12.3 days
overall) and a median wait of 14 days compared with 10 overall.
Three of these women waited over 1 month, and one several
months, for a first appointment.
Government targets relating to the second part of the patient
pathway, from first hospital appointment to treatment, were not
introduced until 2000. Our data showed that the median wait for
first treatment was 4 days longer, and the proportion treated
within 5 weeks of first hospital appointment was 3.5% less, after
the introduction of the 2-week target for the referral wait in 1999.
One explanation for this might be that the pressure to shorten the
referral wait, without additional resources being available in
hospitals to deliver an improved service, has led to delays in
treatment. The effects we have observed reflect the risks inherent
in a policy of targeting one element of the patient pathway in
isolation. The new targets, covering the whole of the patient
pathway from GP referral to treatment, should be better able to
ensure an improved patient experience.
The proportion meeting the target is generally higher for
the treatment wait than for the referral wait, partly because
the diagnosis is established by the beginning of the second
interval. The tumours have by this time been confirmed as
malignant, and are therefore all considered urgent. There may
also be more flexibility within the longer second target period
to compensate for small hold-ups at various points along the
pathway.
The observed age effect on the referral wait, with waiting times
significantly shorter in the age group 50–64 years, may be due to
screening–screen-detected patients had shorter waits for out-
patient appointments. Likewise, the increased proportion of cases
in the oldest age group meeting the target for the treatment wait
may be due to treatment modality– older patients are more likely
to receive tamoxifen as a first treatment, and there was little or no
delay in starting this.
Treatment wait was significantly influenced by only two
factors–it was shorter in high throughput hospitals, and highly
dependent on the type of first treatment. Although the majority of
the breast cancer cases in our study (93%) received surgery or
tamoxifen as their first treatment, the small group of women who
received radiotherapy as their first treatment experienced long
delays, with little more than half being treated within the target
time of 5 weeks. Moreover, the situation deteriorated following the
introduction of the government targets, with median waiting times
for radiotherapy increasing from 29 to 43 days.
There was also a greater proportion of treatment waiting times
for radiotherapy (14%) that had been excluded as being longer
than 6 months, compared to other treatment modes (1%). Had
these cases been left in the analysis, then the disparity would have
been even greater.
A combined analysis of data from 21 breast cancer studies
(Huang et al, 2003) has shown that delay in the initiation of
radiotherapy is associated with an increase in the 5-year local
recurrence rate. Although additional resources have been allocated
within the NHS for radiotherapy, there is still a shortage of trained
radiographers and a recent survey by the Royal College of
Radiologists has shown that treatment delays are increasing
(Browne, 2002).
On the other hand, data from the most recent year of our audit
(2001) show considerable improvements for radiotherapy waiting
times, with a median delay of 18 days and 75% of cases being
treated within 5 weeks of their first hospital appointment.
Tamoxifen was the first form of treatment in 26% of cases,
surgery in 68%, chemotherapy in 6% and radiotherapy in less than
1%. These proportions were dependent on age: in women aged
o65 years at referral, 79% had surgery and 12% tamoxifen as
first treatment, whereas in those aged 65 or over the corresponding
proportions were 51 and 47%, respectively. Of the ‘tamoxifen first’
cases, 47% had subsequent surgery (with a median subsequent
wait of 27 days), 11% had chemotherapy (median wait 56 days)
and 20% radiotherapy (median wait 120 days).
In our data, there were no significant changes in the proportions
receiving different kinds of treatment following the government
mandate, suggesting that the observed overall increases in
treatment waits are not due to changes in treatment policy.
Indeed, increases in median waiting times were observed for all
treatment modalities.
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Figure 3 Referral wait distributions by mode of presentation (July
1997–December 2000).
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Figure 4 Treatment wait distributions by type of treatment (July 1997–
December 2000).
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Our results give a clear message about the need to explore in
detail the statistics used to represent performance on waiting
times. While the simple summary measures employed produce
broadly consistent results, the ‘proportion meeting a target’ is a
poor statistic to represent the experience of the group of patients
as a whole. Median waits can also be insensitive to changes in the
tails of the distributions. The Kaplan–Meier plots are both
informative for the population as a whole and sensitive enough
to show differences in the experience of subgroups within the
population.
Not all 28 hospitals in our area were represented in the study.
Only those women attending the 19 hospitals that consistently
supplied data of sufficiently high quality for the comparative audit
were included. If there were any correlation between organisation
of the audit and organisation of the patient pathway in hospitals,
then this analysis may be biased in favour of overestimating the
improvement in waiting times as a result of the government’s
strategy. Indeed, analysis of the data from the excluded hospitals
tends to corroborate this, with smaller increases or greater
decreases in the proportions meeting the relevant targets.
By definition, all the women in our analysis had a treatment date
of some kind recorded. However, to be classified as the mode of
first treatment, any particular treatment type would need to have a
nonmissing date for the start of that treatment. In general, these
dates were well recorded with the poorest being for radiotherapy,
where only 63% of the cases known to have received radiotherapy
had a corresponding date present. It is therefore possible that
some of these cases may have been misclassified, but as most
would have undergone previous surgery any resulting bias is likely
to be small.
Our study describes the experience of women who have been
diagnosed with breast cancer, as opposed to those suspected of
having breast cancer. As such, we felt it was appropriate to include
screen-detected cases. Reanalysis after excluding screening cases
does not materially affect any of our findings. Some 20% of the
lesions in our screen-detected cases were in situ carcinomas,
compared with 5% in nonscreening cases. It is perhaps ironic
therefore that the screening cases should enjoy more rapid access
to services than clinical cases. Our study adds weight to the fears
that because many breast cancers present among symptomatic
‘nonurgent’ cases, the waits after screening give a falsely optimistic
picture.
The targets in the NHS Cancer Plan to reduce the wait from
referral to first appointment look achievable, but a guaranteed
minimum wait for 100% of patients is almost impossible (Jones,
2001). Even with substantial overprovision of appointment slots,
random variations in demand will exceed supply at times. In
contrast, a 95% or even 99% target is practicable provided the
number of GP referrals does not increase as waits decrease. Waits
for treatment are more amenable to planning (Thomas and Burnet,
2001), as the number of cancer patients per annum (the incidence
rate) is fairly stable. Reducing waits for treatment is also more
valuable to patients in terms of survival outcomes (Richards et al,
1999) and tumour control (Wyatt et al, 2003).
Our data show that waiting times can be shortened, and the
additional resources made available since 2000 within the NHS
Cancer Plan, along with the introduction of targets for waiting
times from GP referral to treatment, should assist hospitals in
speeding up the whole of the patient pathway.
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